SCHEMBL2834011

SCHEMBL2834011

CC(C)=CCOC(=O)c1ccccc1F

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP1 P03956 1/20 0.49
MMP2 P08253 1/20 0.49
MMP9 P14780 1/20 0.49
MMP12 P39900 1/20 0.49
CYP3A4 P08684 1/20 0.49
ADRB2 P07550 5/20 0.48
ADRB1 P08588 5/20 0.48
ADRB3 P13945 5/20 0.48
TP53 P04637 1/20 0.47
HTT P42858 1/20 0.47
ALDH1A1 P00352 4/20 0.46
KDM4E B2RXH2 1/20 0.46
LMNA P02545 1/20 0.46
NPC1 O15118 1/20 0.45
TSHR P16473 2/20 0.44
CES2 O00748 1/20 0.44
CES1 P23141 1/20 0.44
KMT2A Q03164 1/20 0.43
HSD17B10 Q99714 1/20 0.43
MAPK1 P28482 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL541270 0.82 TDP1 (0.57) MMP1MMP2MMP9MMP12CYP3A4
SCHEMBL1867566 0.82 TDP1 (0.57) MMP1MMP2MMP9MMP12CYP3A4
SCHEMBL2834462 0.82 MMP1 (0.54) MMP1MMP2MMP9MMP12HTT
SCHEMBL867867 0.82 ALDH1A1 (0.56) MMP1MMP2MMP9MMP12CYP3A4
SCHEMBL2835187 0.81 TDP1 (0.50) MMP1MMP2MMP9MMP12ALDH1A1
SCHEMBL2832881 0.81 CYP3A4 (0.49) CYP3A4ADRB2ADRB1ADRB3TP53
SCHEMBL2832882 0.81 CYP3A4 (0.49) CYP3A4ADRB2ADRB1ADRB3TP53
SCHEMBL1456587 0.80 CYP3A4 (0.77) CYP3A4ADRB2ADRB1ADRB3TP53
SCHEMBL31069707 0.78 ALDH1A1 (0.73) MMP1MMP2MMP9MMP12CYP3A4
SCHEMBL18867935 0.78 TSHR (0.74) ADRB2ADRB1ADRB3TP53HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101595082-B Ester compound, and non-aqueous electrolyte solution and lithium secondary battery each using the ester compound UBE INDUSTRIES 2013-08-21 CN disclosed
US-8263268-B2 Ester compound, and non-aqueous electrolyte solution and lithium secondary battery each using the ester compound UBE INDUSTRIES, LTD. (JP) 2012-09-11 US disclosed
EP-2108640-B1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND UBE INDUSTRIES (JP) 2012-07-25 EP disclosed
US-20100119955-A1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND UBE INDUSTRIES, LTD. (JP) 2010-05-13 US disclosed
EP-2108640-A1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND Ube Industries, Ltd. (JP) 2009-10-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100119955-A1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND CEL, LAGE3, PEF1 MMP1 1384/4885MMP2 1012/4885MMP9 389/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.